UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000049707 |
|---|---|
| Receipt number | R000056620 |
| Scientific Title | Comparison of postoperative nausea and vomiting between general anesthesia with remimazolam and general anesthesia with propofol: A randomized non-inferiority trial. |
| Date of disclosure of the study information | 2022/12/06 |
| Last modified on | 2024/02/06 14:57:01 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Comparison of postoperative nausea and vomiting between general anesthesia with remimazolam and general anesthesia with propofol: A randomized non-inferiority trial.
Acronym
Comparison of postoperative nausea and vomiting between general anesthesia with remimazolam and general anesthesia with propofol: A randomized non-inferiority trial.
Scientific Title
Comparison of postoperative nausea and vomiting between general anesthesia with remimazolam and general anesthesia with propofol: A randomized non-inferiority trial.
Scientific Title:Acronym
Comparison of postoperative nausea and vomiting between general anesthesia with remimazolam and general anesthesia with propofol: A randomized non-inferiority trial.
Region
| Japan |
Condition
Condition
Patients undergoing surgery under general anesthesia who do not receive postoperative opioids by epidural analgesia nor intravenous PCA.
Classification by specialty
| Anesthesiology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
We compare remimazolam-based and propofol-based total intravenous anesthesia on the incidence of postoperative nausea and vomiting.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
the incidence of postoperative nausea and vomiting for 3 hours and 24 hours after the surgery.
Key secondary outcomes
rescue antiemetic use, severity of nausea ,timing of onset of PONV
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Single blind -participants are blinded
Control
Active
Stratification
YES
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
2
Purpose of intervention
Prevention
Type of intervention
| Medicine |
Interventions/Control_1
remimazolam-based total intravenous anesthesia
Interventions/Control_2
propofol-based total intravenous anesthesia
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| 80 | years-old | > |
Gender
Male and Female
Key inclusion criteria
American Society of Anesthesiologists(ASA) physical status of I-III.
Key exclusion criteria
Patients with severe cardiac, renal, or hepatic dysfunction, severe anemia, and allergies to remimazolam or propofol.
Target sample size
110
Research contact person
Name of lead principal investigator
| 1st name | Hiroshi |
| Middle name | |
| Last name | Yamashita |
Organization
Kobe city medical center general hospital
Division name
department of anesthesiology
Zip code
6500047
Address
Kobe city Chuouku Minatojimaminamichou2-1-1
TEL
0783024321
cantateveritas@kcho.jp
Public contact
Name of contact person
| 1st name | Hiroshi |
| Middle name | |
| Last name | Yamashita |
Organization
Kobe city medical center general hospital
Division name
department of anesthesiology
Zip code
6500047
Address
Kobe city Chuouku Minatojimaminamichou2-1-1
TEL
0783024321
Homepage URL
cantateveritas@kcho.jp
Sponsor or person
Institute
Kobe city medical center general hospital
Institute
Department
Personal name
Funding Source
Organization
Kobe city medical center general hospital
Organization
Division
Category of Funding Organization
Local Government
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kobe city medical center general hospital
Address
Kobe city Chuouku Minatojimaminamichou2-1-1
Tel
0783024321
cantateveritas@kcho.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2022 | Year | 12 | Month | 06 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
91
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Terminated
Date of protocol fixation
| 2022 | Year | 12 | Month | 06 | Day |
Date of IRB
| 2023 | Year | 05 | Month | 08 | Day |
Anticipated trial start date
| 2023 | Year | 05 | Month | 08 | Day |
Last follow-up date
| 2024 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2022 | Year | 12 | Month | 06 | Day |
Last modified on
| 2024 | Year | 02 | Month | 06 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056620
